- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer CenterNCI CANCERLIT® Search: Islet Cell Carcinoma - March 2002
National Cancer Institute®
Last Modified: March 1, 2002
Table of Contents
1
UI - 11779995
AU - Solivetti FM; Giunta S; Caterino M; De Majo A; Coscarella G; Carducci M
TI -
[CT findings in a case of glucagonoma with necrolytic migrating
erythema]
SO - Radiol Med (Torino) 2001 Nov-Dec;102(5-6):410-2
AD - Servizio di Radiologia,IRCCS Istituto Dermosifilopatico di Santa Maria e
San Gallicano, IFO, Rome, Italy.
2
UI - 11808217
AU - Tsuzuki Y; Ishii H
TI -
[Insulinoma--a statistical review of 358 cases of insulinoma reported
from 1991 to 2000 in Japan]
SO - Nippon Rinsho 2001 Dec;59 Suppl 8():121-31
AD - Department of Internal Medicine II, National Defense Medical College.
3
UI - 11740056
AU - Lam K; Lo C; Wat M; Fan ST
TI -
Malignant insulinoma with hepatoid differentiation: a unique case with
alpha-fetoprotein production.
SO - Endocr Pathol 2001 Fall;12(3):351-4
AD - Department of Pathology, University of Hong Kong Medical Center, Queen
Mary Hospital. akylam@hotmail.com
Hepatoid carcinomas are uncommon extra-hepatic neoplasms exhibiting
features of hepatocellular carcinoma and they are most frequently
described in the stomach. We report a 64-year-old woman with a malignant
insulinoma showing focal hepatoid differentiation and biochemical
evidence of alpha-fetoprotein (AFP) production. The current case is the
first malignant insulinoma with hepatoid differentiation. Resection of
the primary tumor followed by regional embolization was peformed. The
patient died 22 months after initial presentation. Thus, the presence of
hepatoid differentiation in pancreatic tumor should be noted as the
tumor may be associated with elevated AFP. The features of pancreatic
hepatoid carcinomas are discussed.
4
UI - 11589679
AU - Brandle M; Pfammatter T; Spinas GA; Lehmann R; Schmid C
TI -
Assessment of selective arterial calcium stimulation and hepatic venous
sampling to localize insulin-secreting tumours.
SO - Clin Endocrinol (Oxf) 2001 Sep;55(3):357-62
AD - Division of Endocrinology and Diabetes, Department of Internal Medicine,
University Hospital Zurich, Switzerland. mbrandle@umich.edu
OBJECTIVE: Non-invasive localization modalities such as ultrasound,
computed tomography (CT) or magnetic resonance imaging (MRI) often fail
to localize insulinomas smaller than 2 cm in diameter. Recent studies
have shown that the selective arterial stimulation and hepatic venous
sampling (ASVS) technique using intra-arterial calcium as the insulin
secretagogue facilitates the regionalization of such occult insulinomas.
This study assesses the sensitivity of ASVS in localizing
insulin-secreting tumours. SUBJECTS AND METHODS: Eleven consecutive
patients (8 women), aged 29-82 years, were studied over the past 4 years
at our hospital. Hyperinsulinaemic hypoglycaemia due to an
insulin-secreting tumour was proven in all patients. Calcium gluconate
(0.025 mEq/kg body weight) was injected directly into the arteries
supplying the pancreas and the liver. Insulin levels were measured in
samples taken from the right hepatic vein before and 30, 60 and 120 s
after each injection. The ASVS technique was performed in all 11
patients; the results were compared with the surgical findings in 10
patients and the autopsy findings in 1 case. The ASVS results were also
compared with the findings of other, previously performed imaging
modalities. RESULTS: ASVS correctly localized 4 insulin-secreting
tumours to the head, 3 to the body, 1 to the tail, 2 to the tail or body
of the pancreas and 1 to the liver. Thus, the sensitivity was 100%
(11/11) whereas other localization techniques were less sensitive: 7/11
tumours were detected by angiography, 4/8 by endosonography, 3/8 by CT
and 1/6 by MRI. Insulinomas (confirmed by histological examination),
sized 4-25 mm, were found in 10 patients. All were cured by selective
surgery and remained free of hypoglycaemia over the next 1-4 years of
follow-up. An insulin-secreting neuroendocrine tumour in the liver was
documented in 1 case at autopsy. CONCLUSIONS: Arterial stimulation and
hepatic venous sampling is a very sensitive technique for preoperative
localization of insulin-producing tumours. It can help to plan minimally
invasive surgery and to select an appropriate strategy for patients
suffering from malignant tumours in others.
5
UI - 11874403
AU - Matson MB; Reznek RH
TI -
Assessment of selective arterial calcium stimulating and hepatic venous
sampling to localize insulin-secreting tumours.
SO - Clin Endocrinol (Oxf) 2002 Feb;56(2):149-50
AD - Barts and The London NHS Trust, UK.
6
UI - 11859446
AU - Meier JJ; Hucking K; Gruneklee D; Schmiegel W; Nauck MA
TI -
[Differences in insulin secretion facilitate the differential diagnosis
of insulinoma and factitious hypoglycaemia]
SO - Dtsch Med Wochenschr 2002 Feb 22;127(8):375-8
AD - Medizinische Universitatsklinik, Knappschaftskrankenhaus, Bochum,
Germany.
HISTORY: A 33-year-old female nurse (married; two children; BMI 30.9
kg/m2) had recurrent episodes of symptomatic hypoglycaemia over some
months. INVESTIGATIONS: Two fasting tests were terminated after 26 hours
because the patient became unconscious. Improved insulin/glucose ratio
was infinity and 6.1 [mU/l]/[mg/dl] (normal value < 0.5). An
hyperinsulinaemic-hypoglycaemic angle "clamp test" produced a C-peptide
suppression to minimally 0.26 - 0.38 nmol/l (normal value 0.06 +/- 0.01
nmol). There was no spontaneous or paradoxical burst in insulin or
C-peptide concentration after either the fasting or the "clamp test".
Serum analysis of sulphonylurea on several occasions documented an
increase of glibenclamide above therapeutic range. TREATMENT AND COURSE:
The patient denied any intake of oral antidiabetic preparations, but
there were no further hypoglycaemia attacks in subsequent months.
DIAGNOSIS: The demonstration of sulphonylurea in serum confirmed the
diagnosis of factitious hypoglycaemia. CONCLUSION: With regard to
insulin or C-peptide suppression, the results of the fasting and clamp
tests are the same in factitious hypoglycaemia and insulinoma. However,
under the influence of sulphonylurea drugs there are no insulin or
C-peptide bursts so typical of insulinoma. In case of doubt, detection
of sulphonylurea preparations in serum or urine is the only reliable way
of diagnosing factitious hypoglaema due to the ingestion of
sulphonylurea.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
